News and Views

RNS Number : 8689W
W.H. Ireland Group PLC
24 April 2019
 

 

 

WH Ireland Group Plc

 

(“WH Ireland” or the “Company”)

 

PDMR shareholding

 

Simon Lough, non-executive director, has informed the Company that he has purchased 94,880 ordinary shares in the Company as set out below. Following these purchases, Simon Lough owns 215,001 ordinary shares, representing 0.50 per cent. of the issued share capital in the Company.

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

1

Details of the person discharging managerial responsibilities

a)

Name

Simon Lough

2

Reason for the notification

a)

Position/status

Non-executive director

b)

Initial notification/amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

WH Ireland Group plc

b)

LEI

213800HB9TO5O4WD6S66

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.5 pence each

 

GB0009241885

b)

Nature of the transaction

Market purchases

c)

Price(s) and volume(s)

Price(s)

Volume(s)

48p per share

94,880



d)

Aggregated information

–   Aggregated volume

 –   Price

 

94,880

£45,542.40

e)

Date of the transaction

17th April 2019

f)

Place of the transaction

London Stock Exchange (XLON)

 

For further information please contact:

WH Ireland Group plc

www.whirelandplc.com

Phillip Wale, Chief Executive Officer

+44(0) 20 7220 1666

 

 

SPARK Advisory Partners Limited (Nominated Adviser)

 

 

Mark Brady/Miriam Greenwood

+44(0) 20 3368 3551

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 

END

 
 

DSHLFFFISVIVFIA